MARKET

XENE

XENE

Xenon Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.52
-0.03
-0.26%
After Hours: 10.85 -0.67 -5.82% 18:06 12/03 EST
OPEN
11.55
PREV CLOSE
11.55
HIGH
11.69
LOW
10.89
VOLUME
199.38K
TURNOVER
--
52 WEEK HIGH
18.45
52 WEEK LOW
7.00
MARKET CAP
403.28M
P/E (TTM)
-13.0331
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions
Biotech stocks had a rather uneventful week, as the sector was seen mostly flatlining amid light trading volume ahead of the Thanksgiving holiday.
Benzinga · 4d ago
Gordon Keller Receives the 2020 Bloom Burton Award
Toronto, Ontario--(Newsfile Corp. - November 26, 2020) - Bloom Burton & Co. is pleased to announce Dr. Gordon Keller as the recipient of the 2020 Bloom Burton Award. Dr. Keller's pioneering academic work in the stem cell therapy field led to the founding of BlueRock Therapeutics in 2016, which was ultimately acquired by Bayer for $1 billion in 2019. BlueRock Therapeutics built out a major laboratory in Toronto, where more than 170 world-class scientists have been recruited to bring new therapies to market for cardiovascular and other diseases. Dr. Keller is the Director of the McEwen Stem Cell Institute at the University Health Network, a Senior Scientist at the Princess Margaret Cancer Centre, a Professor in the Department of Medical Biophysics at the University of Toronto, and holds the Tier I Canada Research Chair in Embryonic Stem Cell Biology.
Newsfile Corp · 11/26 12:16
Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will participate in the following virtual investor conferences:
GlobeNewswire · 11/13 14:00
Xenon Pharmaceuticals (XENE) Reports Q3 Loss, Lags Revenue Estimates
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -66.67% and -36.54%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/05 23:45
Xenon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Experienced Biotech Executive, Patrick Machado, Joins Xenon's Board of Directors
GlobeNewswire · 11/05 21:03
Xenon Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 5, 2020 / Xenon Pharmaceuticals, Inc. (NASDAQ:XENE) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 5, 2020 at 4:30 PM Eastern Time.
ACCESSWIRE · 11/05 19:48
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2020 Financial Results and Provide Corporate Update
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that it will report its third quarter 2020 financial and operating results after the close of U.S. financial markets on Thursday, November 5, 2020. Xenon management will host a conference call and live audio webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the results and to provide a corporate update.
GlobeNewswire · 11/02 22:25
Merck Reports Positive HIV Data, And Other News: The Good, Bad And Ugly Of Biopharma
Merck reports positive mid-stage data for HIV combo therapy.Takeda collaborates with Arrowhead Pharma for liver disease program.Xenon Pharmaceuticals receives FDA feedback for XEN496 phase 3 clinical trial.
Seekingalpha · 10/13 05:26
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XENE. Analyze the recent business situations of Xenon Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XENE stock price target is 23.00 with a high estimate of 25.00 and a low estimate of 22.00.
EPS
Institutional Holdings
Institutions: 110
Institutional Holdings: 30.78M
% Owned: 87.93%
Shares Outstanding: 35.01M
TypeInstitutionsShares
Increased
15
1.25M
New
11
-114.54K
Decreased
28
1.20M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.07%
Pharmaceuticals & Medical Research
+0.39%
Key Executives
Chairman/Independent Director
Michael Tarnow
President/Chief Financial Officer/Secretary
Ian Mortimer
Chief Executive Officer/Director
Simon Pimstone
Executive Vice President
Robin Sherrington
Senior Vice President/Director of Human Resources
Shelley McCloskey
Senior Vice President
James Empfield
Other
Ernesto Aycardi-Fonseca
Independent Director
Mohammad Azab
Other
Ernesto Aycardi
Independent Director
Clarissa Desjardins
Independent Director
Steven Gannon
Independent Director
Michael Hayden
Independent Director
Frank Holler
Independent Director
Gary Patou
Independent Director
Dawn Svoronos
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About XENE
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD). Specifically, it is intended to treat LPLD in patients with severe or multiple pancreatitis attacks, despite dietary fat restrictions. TV-45070 is a small-molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, including those that are expressed in the pain-sensing peripheral nervous system. XEN901 is developed for the treatment of rare infantile epileptic encephalopathy and other forms of epilepsy. XEN1101, is a potassium channel modulator for the treatment of epilepsy. Its Extreme Genetics discovery platform enables the Company to identify drug targets that are more biologically relevant in humans.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Xenon Pharmaceuticals Inc stock information, including NASDAQ:XENE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XENE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XENE stock methods without spending real money on the virtual paper trading platform.